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ABSTRACT
Objective To estimate the effect of a physiotherapist-
delivered fall prevention programme for people with 
parkinson’s (pwp).
Methods people at risk of falls with confirmed 
parkinson’s were recruited to this multicentre, pragmatic, 
investigator blind, individually randomised controlled 
trial with prespecified subgroup analyses. 474 pwp 
(hoehn and Yahr 1–4) were randomised: 238 allocated 
to a physiotherapy programme and 236 to control. all 
participants had routine care; the control group received 
a DVD about parkinson’s and single advice session at 
trial completion. The intervention group (pDsaFe) had 
an individually tailored, progressive home-based fall 
avoidance strategy training programme with balance and 
strengthening exercises. The primary outcome was risk 
of repeat falling, collected by self-report monthly diaries, 
0–6 months after randomisation. secondary outcomes 
included Mini-BesTest for balance, chair stand test, falls 
efficacy, freezing of gait, health-related quality of life 
(euroQol eQ-5D), Geriatric Depression scale, physical 
activity scale for the elderly and parkinson’s Disease 
Questionnaire, fractures and rate of near falling.
Results average age is 72 years and 266 (56%) were 
men. By 6 months, 116 (55%) of the control group 
and 125 (61.5%) of the intervention group reported 
repeat falls (controlled OR 1.21, 95% cI 0.74 to 1.98, 
p=0.447). secondary subgroup analyses suggested a 
different response to the intervention between moderate 
and severe disease severity groups. Balance, falls efficacy 
and chair stand time improved with near falls reduced in 
the intervention arm.
Conclusion pDsaFe did not reduce falling in this 
pragmatic trial of pwp. Other functional tasks improved 
and reduced fall rates were apparent among those with 
moderate disease.
Trial registration number IsRcTN48152791.
InTROduCTIOn
Parkinson’s disease (PD) is a progressive neuro-
logical condition that affects more than 10 million 
people worldwide; falls are common in this group. 
Prior to the start of the PDSAFE trial, a meta-anal-
ysis of fall reduction among the general older popu-
lation1 demonstrated a positive exercise effect but it 
was not until during PDSAFE that a meta-analysis 
of fall prevention among people with Parkinson’s 
(PwP) was published2; findings were inconsistent 
with small overall effect sizes on fall rate ratios 
(FRR) and group-based training more favourable 
than home-based interventions.3–8
Falls are twice as common among PwP as the 
healthy aged.1 7–10 Impairments of gait, including 
freezing of gait, cognition and loss of postural 
control, are common risk factors for falling in this 
population, balance and falls are not easily reme-
died by medication.11 12 The effects of falls in PwP 
can be profound including loss of mobility, poor 
function in activities of daily living, fractures and 
increased care needs7–9 12 13 as well as being costly 
to both individuals and health services.14 There is 
some evidence that exercise may be useful for fall 
prevention in PwP.2 However, trials conducted to 
date have usually been small, only 6 out of 25 trials 
in the meta-analysis recruited 100 or more partic-
ipants. Most of the larger trials were negative2 but 
there were differences in subgroup responses6–8; 
benefits were demonstrated in higher functioning 
groups, particularly in people who had suffi-
cient function to enable them to travel to exercise 
venues and participate in group programmes.6 
Canning et al6 recruited 231 PwP to a randomised 
controlled trial (RCT) and reported non-signifi-
cant overall effect but significant interaction with 
disease severity; those with more severe disease had 
a greater number of falls following intervention, 
while there was significant improvement for those 
with less severe disease.
Our aim was to compare the effect on repeat 
falling outcomes and other outcomes of an individ-
ualised, progressive exercise intervention delivered 
in people’s own home, in addition to usual care. We 
aimed to recruit a large, pragmatic sample of PwP, 
and used prespecified and exploratory subgroup 
analysis to examine variation in the intervention 
effect according to baseline disease severity and 
freezing of gait.
MeThOdS
Study design
A full protocol has been published.15 This was 
a multicentre, pragmatic, investigator-masked 
RCT. Participants were recruited from Parkinson’s 
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services in National Health Service hospitals and clinics, commu-
nity and social services in eight regions across England: Bour-
nemouth and Poole, Truro, Plymouth, Exeter, Winchester and 
Basingstoke, Newcastle, Portsmouth and Southampton. We also 
identified recruits via the study website. We delivered interven-
tions in the participant’s home. The primary endpoint for the 
trial was 6 months after randomisation. We received funding to 
allow 12-month follow-up on the first 342 recruited into the 
trial. An economic evaluation and a nested qualitative study 
of the views of participants will be published elsewhere as will 
details of the intervention. Trial management, data monitoring 
and statistical analyses were coordinated at the PDSAFE trial 
office, University of Southampton, UK and supported by the 
Oxford Clinical Trials Research Unit (OCTRU).
Participants
People were eligible if they had a clinically confirmed diagnosis of 
Parkinson’s disease in accordance with UK Brain Bank criteria16; 
were living in their own home; independently mobile with or 
without an aid; experienced at least one fall in the previous 12 
months; scored 24 or more on Mini-Mental State Examination17 
(MMSE); had the cognitive ability to give informed consent; 
were able to understand and follow commands; and considered 
able to participate in an exercise and strategy programme.
Interventions
All participants continued to receive usual care including medi-
cation management, and took part in their usual activities, such 
as exercise or social groups. Participants assigned to the control 
group were given a Parkinson’s UK DVD with information about 
Parkinson’s. At the end of their time in the trial, control partic-
ipants received a single session on fall avoidance and a booklet 
on falls management.
PDSAFE18 comprised individually tailored, progressive home-
based exercise and strategies to avoid falls, for example, ‘Stepping 
patterns and sideways stepping in small complex areas to avoid 
tripping’. Registered physiotherapists made visits to the partic-
ipants’ home to provide 12 supervised sessions of 1–1.5 hours 
duration over 6 months. More supervised sessions were deliv-
ered early in the programme, and gradually tapered over time. 
From the start of the programme, participants were expected to 
engage in daily unsupervised exercise for about 30 min, and were 
provided with a prescription for these and strategies to maximise 
adherence, such as integration into daily routines. Participants 
were given a folder with pictures and descriptions of exercises, 
a rating of perceived exertion scale, an exercise log, and DVDs 
of both exercise demonstrations and personal videos taken by 
their physiotherapist of them doing the exercises. Programmes 
were based on an individualised assessment of fall risk factors, 
including the home environment and high-risk activities. Exer-
cises included balance training with a gradual decrease in the 
area of support and use of foam standing pads. Strength training 
used body weight resistance, and if appropriate, weighted 
vests, during functional exercises (sit to stand). Strategies for 
fall and freezing avoidance included transfer practice (turning) 
in complex environments such as bathrooms and kitchen and 
adopting wide-based positions during functional task practice.
Intervention fidelity was promoted through a 2-day training 
session, and subsequent observation and feedback during 
sessions by a specialist physiotherapist with expertise in Parkin-
son’s management. All but one physiotherapist had a back-
ground in neurological practice. Monthly ‘master classes’, 
weekly teleconferences and regular clinical supervision sessions 
were implemented. Fidelity checks were undertaken three times 
during a therapist’s first 3 months of delivering the intervention, 
and three times monthly thereafter. We considered that people 
who attended the assessment and received one home session 
to have engaged with the intervention. Those who had seven 
or more sessions were considered to have complied with the 
intervention.
Outcomes
The primary outcome was risk of repeat falling in the first 6 
months after randomisation. A fall was defined as an event 
which resulted in a person coming to rest unintentionally on 
the ground or lower level.19 Secondary outcomes were fractures 
and the rate of near falling; the Mini-BESTest20 (high values—
good, a test of balance control); the chair stand test (CST)21 (low 
timing—good); medication use; the Geriatric Depression Scale 
(GDS)22 (15 questions version; low scores—good); the Interna-
tional version of the Falls Efficacy Scale (FES)23 (low scores—
good); the New Freezing of Gait Questionnaire (NFoG) 24 (low 
scores—good); the Parkinson’s Disease Questionnaire (PDQ-
39)25 (low scores—good, a quality of life measure designed 
specifically for PwP); the Physical Activity Scale for the Elderly 
(PASE)26 (high scores—good) at 6 months; and the EuroQol 
(EQ-5D-3L) health-related quality of life instrument.27 We 
recorded all deaths, any hospitalisations were recorded at assess-
ment and serious adverse events were reviewed by a medical 
physician (HR). The PASE, PDQ-39 and GDS were self-com-
pleted and returned by post.
Randomisation and blinding
Prior to randomisation, participants completed 3 months of fall 
diaries. We then did a baseline assessment after which partici-
pants were randomly assigned (50:50) to either the intervention 
or control group, using an online procedure set up by OCTRU 
(a UK Clinical Research Collaboration registered trial unit). 
The allocations were sent to the trial manager who informed a 
treating therapist, to ensure allocation concealment from trial 
recruiters and assessors. Random allocations were computer 
generated, stratified by centre and allocated in blocks with 
random size of 2, 4, 6 or 8. The trial manager, the treating ther-
apists and the participants were not blinded to the allocated 
group. At each point of contact, participants were asked not to 
divulge their group allocation to trial assessors who were blind 
to group allocation.
Procedure
We trained registered healthcare professionals to assess eligi-
bility of potential participants, to register and randomise partic-
ipants, to collect baseline information and administer outcome 
measures during the follow-up period; fidelity checks were 
routinely made. We collected eligibility and baseline data over 
two visits, separated by a 3-month period in which we asked 
participants to collect falls diary data. At the first eligibility visit 
we collected the Montreal Cognitive Assessment (MoCA),28 
the number of falls experienced over the previous 12 months, 
the MMSE,17 the Hoehn and Yahr Scale of disease severity,29 
demographics and medical history. At the second visit, we 
rechecked consent, collected the Unified Parkinson’s Disease 
Rating Scale (UPDRS)30 (low scores—good, motor section only) 
and enrolled and randomised the participant. Participants were 
asked to complete monthly diaries through the follow-up period 
and face-to-face assessments were taken to collect all other data 
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during home visits at 6 months, and for those completing the 
extended follow-up at 12 months.
Sample size calculation
Based on the results of a previous trial8 we assumed the risk 
of repeat falling between 0 and 6 to be 50% in the interven-
tion group and 63% in the control group, yielding a sample size 
requirement of 228 participants per group at 80% power in a 
two-sided 5% comparison of proportions. Allowing for 15% 
(10% before randomisation and 5% after) loss to follow-up, 
for these participants, between approach, randomisation and 6 
months, we aimed to recruit 534 participants to the prerandomi-
sation falls collection period.
Statistical analysis
A statistical analysis plan was finalised before the data set was 
locked. The analysis was intention to treat in that all participants 
were analysed in the group to which they were randomised. 
For the primary outcome, we included participants who had 
completed a minimum of 50% of diaries (as recommended by 
Goodwin et al7) and missing falls diary data, for these partici-
pants, by imputing the binary indicator of repeat faller (yes/no) 
from the final assessment if these data were available. The anal-
ysis of rates of falling included all participants with any degree 
of diary completion.
We used logistic regression controlling for site, age, gender, 
Hoehn and Yahr, the logarithm of retrospectively collected 
number of falls in the year prior to screening, repeat fall status 
prior screening, and the logarithm of the prospectively collected 
rate of falling during the 3 months period prior to randomisa-
tion with 0.5 added to numerators so that participants with zero 
falls during the period were included. These controlling variables 
were finalised in a blind analysis without access to the group 
indicator, as specified in the analysis plan. Rates of falling during 
the periods 0–6 and 6–12 months after randomisation were 
examined in negative binomial models with the logarithm of a 
participant’s days of diary follow-up included as an offset. ORs 
and FRRs are presented with 95% CIs. The geometric mean of 
individual participant rates (with 0.5 added to the numerator as 
before) of falling during 6-month follow-up periods is presented 
as rates per 6 months to accommodate the skewed distribution 
across participants. We prespecified subgroup analysis for falling 
between 0 and 6 months to MoCA28 status (≤25 and ≥26), 
freezing status, and disease severity UPDRS30 and Hoehn and 
Yahr.29 In addition, and informed by the findings of Morris et 
al,3 5 we explored subgroup analyses for MoCA, UPDRS and 
number of falls in the year prior to screening using the tertiles 
of the baseline distribution. We tested for subgroup effects using 
statistical tests of interaction. A secondary per protocol analysis 
excluded participants from the PDSAFE group who received less 
than 7 of the planned 12 sessions. Analysis was conducted in 
SPSS version 24 (IBM) and Stata.31
Patient involvement
Patient and Public Involvement (PPI) representatives were 
involved in the design of the study, the development of partic-
ipant information sheets, consent forms and intervention 
resources. A PPI representative was a member of the Trial 
Steering Committee. The trial was discussed at several local 
Parkinson’s support groups and representatives were invited to a 
meeting on interpretation of results and key messages.
ReSulTS
Trial progression and recruitment
Recruitment was from July 2014 to August 2016 (study flow 
summarised in figure 1). A total of 640 PwP were invited to 
participate, 99 either did not respond or did not meet the eligi-
bility criteria leaving 541 for consent and completion of the first 
eligibility visit. At this point, a further seven people did not reach 
the MMSE requirement and were excluded. The remainder went 
on to second eligibility check after which a further 60 people 
were excluded (reasons provided in figure 1). The remaining 
474 completed a baseline assessment and were randomised to 
usual care (n=236) or PDSAFE (n=238). Withdrawal rates were 
low at the primary time point, and equivalent across the groups. 
Falls diary completion was good at the primary time point, with 
203/238 (85%) of the usual care group and 211/236 (89%) of 
the intervention group providing useable data, see online supple-
mentary table 1. The IQR for the number of diary completion 
days over the primary 6-month period was 174–183 and 153–183 
days in the control and intervention groups, respectively. Four-
teen trained assessors completed blinded data collection.
Intervention
Eighteen physiotherapists delivered PDSAFE and compliance 
with the intervention was good. Two hundred and seventeen 
of 238 (91%) participants received per protocol seven or more 
supervised treatment sessions and 75% (162) of those received 
the maximum number. The median number of supervised 
sessions for all participants randomised to the intervention was 
12 (IQR 11–12). The majority of participants, 236/238, received 
the exercise assessment and at least one supervised session. Two 
participants did not start due to a change of mind, 19 received 
less than seven sessions. Reasons for withdrawal from the trial 
included: admission to a nursing home, deteriorating health, 
commitment was too much, no reason given and caring for 
others (see figure 1).
Sample
The baseline characteristics of randomised groups were balanced 
(table 1). There was a difference in the rate of falling in the 
run-in period.
Outcomes
There was little difference in the rate of falling between groups 
in the first 6 months (table 2). Table 3 shows the treatment 
effect estimates for the primary time point including the primary 
outcome. Repeat falling in the PDSAFE group at 6 months was 
slightly higher than in the control group (OR 1.21, 95% CI 0.74 
to 1.98, p=0.447). There was significantly lower risk of near 
falling (0.67, 95% CI 0.53 to 0.86, p=0.001) in the PDSAFE 
compared with the control group.
For the secondary outcomes collected at 6 months (table 3), 
the exercise group had better balance (between-group difference 
Mini-BESTest score 0.95 points, 95% CI 0.24 to 1.67, p=0.009); 
better falls confidence (between-group difference 1.60 points, 
95% CI 3.00 to 0.19, p=0.026); and improved balance and 
functional strength as assessed by the CST (p=0.041) (table 4). 
No material differences from those reported above were found 
when analyses were repeated on a per protocol basis.
Prespecified and exploratory subgroup analysis: 6 months
The results of prespecified subgroup analyses for MoCA and 
freezing of gait are shown in figure 2, along with further anal-
ysis of subgroups defined by tertiles. People who had freezing 
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Figure 1 Flow of participants through the trial. MMse, Mini-Mental state examination.
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Table 1 Baseline characteristics in the PDSAFE and control groups: 
figures are number (%) unless stated otherwise
PdSAFe
(n=238*)
Control
(n=236†)
Gender 
  Male
  Female
147 (62%)
91 (38%)
119 (50%)
117 (50%)
Age (years) 
Mean (SD)
Min to max
71 (7.7)
51 to 91
73 (7.7)
46 to 88
Disease duration (years) 
Mean (SD)
Min to max
8 (6.6)
0 to 36
8 (5.8)
0 to 29
MMSE 
Mean (SD)
Min to max
28 (1.7)
24 to 30
29 (1.6)
24 to 30
MoCA 
Mean (SD)
Min to max
≤25 (cognitively impaired)
26 (2.9)
15 to 30
91 (38%)
26 (3.2)
9 to 30
93 (39%)
Living status 
Lived alone
With a spouse/partner
With a friend/family
48 (20%)
174 (73%)
15 (6%)
59 (25%)
166 (70%)
10 (4%)
Hoehn and Yahr stage 
1
2
3
4
26 (11%)
78 (33%)
102 (43%)
32 (13%)
30 (13%)
56 (24%)
112 (48%)
38 (16%)
UPDRS 
Mean (SD)
Min to max
TD phenotype
PIGD phenotype
Indeterminate phenotype
32 (15.2)
2 to 77
21 (9%)
194 (83%)
20 (8%)
33 (17.3)
4 to 92
19 (8%)
206 (88%)
10 (4%)
Freezing of gait in the past 
month
152 (64%) 139 (59%)
Number of falls in 12 months prior to screening 
Median (min to max)
Mean (SD)
Repeat falling in 12 months
3 (1 to 1460)
26 (132.7)
186 (78%)
3 (1 to 1095)
19 (105.4)
189 (80%)
Rate of falls/person/3 months prior to randomisation 
Median (min to max)
Mean (SD)
  1.98 (0 to 319)
  5.9 (22.8)
  0.99 (0 to 73)
  3.0 (7.3)
Rate of near falls/person/3 months prior to randomisation 
Median (min to max)
Mean (SD)
  4.4 (0 to 440)
  13.8 (35.8)
  4.3 (0 to 601)
  15.6 (51.4)
Medications 
  Levodopa
  Dopamine agonist
  Monoamine oxidase 
inhibitor
  COMT inhibitors
  Other PD medication
  208 (88%)
  108 (46%)
  52 (22%)
  59 (25%)
  19 (8%)
  216 (92%)
  106 (45%)
  46 (20%)
  41 (17%)
  23 (10%)
GDS score at baseline 
>5 (suggestive of depression)
≥10 (indicative of depression)
  147/235 (63%)
  50/235 (21%)
  164/236 (70%)
  49/236 (21%)
Coexisting conditions 
Orthopaedic
Cardio/respiratory
  109 (46%)
  85 (36%)
  129 (54%)
  96 (41%)
Continued
PdSAFe
(n=238*)
Control
(n=236†)
*Missing values in the intervention group: living status (1); UPDRS (1); disease 
duration (1); freezing of gait (1); rate of falling in the 3 months prior to 
randomisation (1); TD/PIGD/Indeterminate phenotype (3).
†Missing values in the control group: living status (1); UPDRS (1); TD/PIGD/
Indeterminate phenotype (1).
GDS, Geriatric Depression Scale; MMSE, Mini-Mental State Examination; MoCA, 
Montreal Cognitive Assessment; PD, Parkinson's disease; UPDRS, Unified Parkinson’s 
Disease Rating Scale.
Table 1 Continued
of gait at study entry did not respond well to the intervention, 
and this interaction effect estimate was statistically significant 
(p=0.025). There were trends towards worse response to treat-
ment in people with cognitive impairment (as measured by the 
MoCA) (p=0.111 and p=0.088 for the analyses of repeat falls 
and rate of falling, respectively).
Statistically significant differences in the PDSAFE effect in 
relation to rate of falling were found across subgroups according 
to UPDRS severity, and retrospectively collected falling in the 
year prior to screening (interaction p=0.009 and 0.050, respec-
tively); with an indication of possible benefit of PDSAFE in 
the middle subgroups only, while PDSAFE was associated with 
increased rate of falling in the most severe group. The impact of 
PDSAFE on near falling, Mini-BESTest and falls confidence was 
consistently beneficial across the subgroups. Additional explor-
atory subgroup analyses are shown in supplementary table 2.
Adverse events and deaths
Two participants died during follow-up in the PDSAFE group 
and five in the control group (figure 1). During the 6 months 
following randomisation, five fractures were reported by 
PDSAFE and nine by control group participants. Nine PDSAFE 
and 20 control group participants reported hospitalisations, 
of whom one PDSAFE participant reported two stays, none of 
these were associated with participation in the intervention.
extended follow up
During the period 6–12 months after randomisation, seven 
fractures were reported by PDSAFE and three by control 
group participants; 18 PDSAFE and 21 control group partici-
pants reported hospitalisations of whom two PDSAFE and four 
control participants reported two hospital stays. No participant 
fell during exercising.
dISCuSSIOn
PDSAFE is the largest trial of physiotherapy for fall prevention 
among PwP, with 474 participants randomised it was more than 
double the size of the previous largest trial by Canning et al6 with 
231 participants. It was novel with a personalised intervention 
conducted in the home setting, and both a 3-month prerandomi-
sation baseline and follow-up counts of falls collected prospec-
tively in diaries. Despite this, we failed to demonstrate PDSAFE 
was effective in reducing falls in a heterogeneous sample of PwP 
overall. Our non-significant result was similar to that found by 
previous researchers of trials with more than 100 participants5–8 
and falls as a primary outcome. The exception was a trial of 
exercises conducted in an outpatient setting by Morris et al in 
2015.3 This positive outcome was not replicated when repeated 
at home with a lower treatment dose.5 Two other research groups 
reported fall reduction as a result of interventions outside of 
current physiotherapy; virtual reality and treadmill training4 and 
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Table 2 Intention-to-treat analysis of falling outcomes: 0–6 and 6–12 months
Period
PdSAFe Control PdSAFe/Control*
OR (95% CI) P value*n (%)
Repeat falling restricted to 
≥50% diaries
Baseline 127/231 (55) 92/230 (40)
Baseline† 112/203 (55) 80/211 (38)
0–6 months 125/203 (62) 116/211 (55) 1.21 (0.74 to 1.98) 0.447
Baseline† 55/114 (48) 47/132 (36)
6–12 months 57/114 (50) 71/132 (54) 0.86 (0.45 to 1.65) 0.657
  Falls/person/6 months‡ FRR (95% CI)
Fall rates Baseline 4.5 3.3
0–6 months 3.4 2.7 0.98 (0.80 to 1.19) 0.824
6–12 months 2.7 2.8 0.83 (0.62 to 1.11) 0.200
  near falls/person/6 months‡ nFRR (95% CI)
Near fall rates Baseline 8.0 8.1
0–6 months 4.7 5.6 0.67 (0.53 to 0.86) 0.001
6–12 months 3.9 3.7 1.01 (0.67 to 1.52) 0.968
*Controlled for site, age, gender, repeat falling or not in the year prior to screening, log number of falls in the year prior to screening, log rate of falling in the prerandomisation 
falls collection period and Hoehn and Yahr (NFRR additionally controlled for log rate of near falling in the prerandomisation falls collection period).
†Baseline repeat falling restricted to participants including in the 0–6 and 6–12 month analyses.
‡Geometric mean of individual fall rates with 0.5 added to all numerators.
FRR, fall rate ratio; NFRR, near fall rate ratio.
Table 3 Secondary outcomes at 6 and 12 months
Visit
Mean (Sd, n)
Mean difference (PdSAFe-
Control) (95% CI)* P value*
PdSAFe
(n=238)
Control
(n=236)
Mini-BESTest
(0–28, lower values worse)
†Baseline
6 months
6 months-baseline
18.3 (5.7, n=183)
19.4 (5.9, n=183)
1.1 (3.8, n=183)
17.3 (6.1, n=211)
17.5 (6.4, n=211)
0.2 (3.8, n=211)
0.95 (0.24 to 1.67) 0.009
†*Baseline
12 months
12 months-baseline
18.5 (5.8, n=115)
17.9 (6.5, n=115)
−0.7 (4.5, n=115)
17.5 (6.1, n=126)
17.4 (6.7, n=126)
−0.2 (3.8, n=126)
−0.41 (−1.48 to 0.66) 0.449
FES-I
(16–64, higher values worse)
†Baseline
6 months
6 months-baseline
34.1 (11.0, n=189)
33.4 (10.6, n=189)
−0.7 (7.9, n=189)
35.1 (11.5, n=211)
36.2 (11.4, n=211)
1.1 (7.2, n=211)
−1.6 (−3.0 to −0.19) 0.026
†*Baseline
12 months
12 months-baseline
33.4 (10.7, n=119)
34.8 (11.2, n=119)
1.3 (8.2, n=119)
33.7 (11.3, n=135)
37.2 (11.6, n=135)
3.5 (9.3, n=135)
−1.4 (−3.41 to 0.66) 0.184
PASE
(0–400, lower values worse)
†Baseline
6 months
6 months-baseline
107.8 (73.5, n=153)
110.2 (70.4, n=153)
2.4 (50.8, n=153)
100.1 (67.1, n=177)
100.6 (68.0, n=177)
0.5 (49.5, n=177)
−1.05 (−11.3 to 9.21) 0.841
†*Baseline
12 months
12 months-baseline
108.1 (71.9, n=98)
99.4 (72.8, n=98)
−8.7 (53.0, n=98)
98.6 (61.1, n=115)
87.6 (62.3, n=115)
−11.0 (48.5, n=115)
−0.55 (−13.9 to 12.8) 0.935
PDQ-39
(0–100, higher values worse)
†Baseline
6 months
6 months-baseline
27.4 (14.3, n=126)
28.3 (15.0, n=126)
0.8 (8.3, n=126)
28.7 (15.9, n=153)
29.5 (16.5, n=153)
0.9 (9.0, n=153)
0.12 (−2.0 to 2.28) 0.911
†*Baseline
12 months
12 months-baseline
27.2 (13.6, n=77)
29.1 (15.4, n=77)
1.9 (8.6, n=77)
28.9 (15.9, n=100)
31.7 (15.5, n=100)
2.8 (11.2, n=100)
0.48 (−2.53 to 3.49) 0.754
GDS
(0–15, higher values worse)
†Baseline
6 months
6 months-baseline
7.7 (2.3, n=154)
7.8 (2.5, n=154)
0.3 (1.8, n=154)
7.7 (2.1, n=183)
8.0 (2.5, n=183)
0.2 (1.9, n=183)
−0.02 (−0.42 to 0.39) 0.942
†*Baseline
12 months
12 months-baseline
7.7 (2.1, n=96)
7.8 (2.5, n=96)
0.2 (2.0, n=96)
8.0 (2.2, n=118)
8.5 (2.4, n=118)
0.4 (1.7, n=118)
−0.21 (−0.72 to 0.31) 0.421
*Controlled for site, age, gender, repeat falling or not in the year prior to screening, log number of falls in the year prior to falling, log rate of falling in the prerandomisation falls 
collection period, Hoehn and Yahr and the outcome in question assessed at baseline.
†Baseline results restricted to existing participant assessment at 6 months.
FES-I, Falls Efficacy Scale International; GDS, Geriatric Depression Scale; PASE, Physical Activity Scale for the Elderly; PDQ-39, Parkinson’s Disease Questionnaire.
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Table 4 Chair stand test (CST) at 6 and 12 months
PdSAFe
(n=238)
Control
(n=236) P value*
Baseline among participants with 
6-month assessment
Unable of those with a CST assessment 29/188 (15%) 35/213 (16%) 0.041
(n=401)CST (s) among those able Median
IQR
14
11–18
(n=159)
14
11–18
(n=178)
6-month assessment Unable of those with a CST assessment 27/188 (14%) 47/213 (22%)
CST (s) among those able Median
IQR
12
10–15
(n=161)
13
10–16
(n=166)
Baseline among participants with 
12-month assessment
Unable of those with a CST assessment 15/119 (13%) 21/134 (16%) 0.163
(n=253)CST (s) among those able Median
IQR
14
11–17
(n=104)
14
12–18
(n=113)
12-month assessment Unable of those with a CST assessment 23/119 (19%) 38/134 (28%)
CST (s) among those able Median
IQR
12
9–14
(n=96)
13
11–15
(n=96)
*Mann-Whitney U test incorporating participants unable to perform test and times from participants able to perform test.
Figure 2 Overall and subgroup analysis of falling, near falling (during 0–6 months) and secondary outcomes (at 6 months). Fes-I, Falls efficacy scale 
International; FRR, fall rate ratio; Mini-BesTest, balance evaluation systems test; Moca, Montreal cognitive assessment; NFRR, near fall rate ratio; UpDRs, 
Unified parkinson’s Disease Rating scale.
tai chi.32 A meta-analysis of fall interventions prior to this trial 
demonstrated an inconsistency of effect with a need for higher 
quality trials.2 In line with those previous researchers of non-sig-
nificant trials, we found a diverse response to the intervention, 
those with milder disease responding better to the intervention 
than those with a more severe condition profile.
It has been suggested that non-significant fall prevention 
trials have resulted from underdosing of treatment3 but dosing 
rehabilitation is complex. Rehabilitation is an interactive educa-
tional process designed to improve function and facilitated by a 
therapist. Each person has to actively participate in rehabilita-
tion, the process of which can be influenced by motivation, age, 
cognition and severity of condition. Other important features 
are timing and content of intervention as well as the therapists 
and training. We will address these issues below and discuss how 
they may have led to the non-significant finding of our trial.
First, the influence of the therapy content and delivery on 
rehabilitation dose. A strength of the trial was the evidence-
based therapy programme delivered by skilled trained physio-
therapists. The PDSAFE training was structured and practice was 
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rigorously tested for fidelity. Ninety-one per cent of the interven-
tion group participants received per protocol on average 12 face-
to-face supervised sessions of 1–1.5 hours and were encouraged 
to complete unsupervised daily practice, meeting the recommen-
dations of Sherrington et al33 of at least 50 hours of practice. 
Previous researchers have used a range of different interventions, 
often poorly described with a great deal of diversity of treatment 
protocols and dosage. The PDSAFE trial delivered more super-
vised sessions than any of the other five identified research trials, 
for example, 1 hour weekly face to face for 6 weeks,5 1 hour 
weekly group session for 8 weeks,6 1 hour weekly group session 
for 10 weeks,7 1 hour monthly group session for 6 months and 
1 hour weekly session for 6 weeks8; in addition, all encouraged 
independent practice but their recommendations were not as 
frequent as the PDSAFE mandate of daily routine. In terms of 
amount of treatment a balance is needed between sufficient 
time for training and too high an expectation of commitment, 
if too high participants start to withdraw and even under our 
procedures we had a greater withdrawal from the intervention 
group than our control group. Our programme was personalised 
in order to maximise individual motivation and it was multidi-
mensional, requiring individuals to progress their activities and 
to integrate their training into everyday functional tasks which 
needed active participation from them and cognitive reasoning 
but this may have been too challenging for some. While manage-
able by those in the moderate to least severe disease groups, 
attention, reaction and response rates may have been compro-
mised at the more severe end of the spectrum even though the 
treatment and selection of tasks were personalised.
Second, the influence of individual characteristics on reha-
bilitation dose. Our sample reflected a typical heterogeneous 
Parkinson’s population and was not dissimilar to the other 
research trials; it comprised participants with a range of disease 
severity and fall events; at least one fall in the previous 12 
months, some with multiple falls and high disease severity or 
more complex symptoms, such as freezing. Within Parkinson’s, 
falls are indicative of a changing disease process; PwP with an 
established pattern of falling will have more global features of 
decline of age and/or disease association. Lord et al34 suggest 
these progressive features create additional challenges for imple-
menting appropriate management and research. Our sample 
typically included those with and without freezing of gait and, 
although we screened to exclude individuals with cognitive 
impairment using the MMSE,17 some participants at baseline and 
subsequent assessments scored low on the MoCA,28 a test known 
to be sensitive to frontal and executive function associated with 
people who fall.35 The motor learning potential is reduced in 
people who freeze36 37 and are cognitively challenged; increasing 
evidence demonstrates that freezing of gait is an important risk 
factor of falls, associated with reduced balance38 and impaired 
cognition. The inclusion of people who did or did not expe-
rience freezing illustrates the diverse range of motor problems 
present in a community sample of PwP and the range of chal-
lenges faced when teaching and learning new skills. Domingos et 
al39 have called for more studies into fall prevention with people 
with impaired cognition.
That exercise is not uniformly effective across all presenta-
tion of Parkinson’s had been suggested but not confirmed in 
three previous smaller trials,6–8 this informed our decision to 
prespecify and undertake subgroup analyses on our data. The 
recent work of Canning et al6 and older trials by Goodwin et al7 
and Ashburn et al8 consistently found in their secondary analysis 
that those with less severe Parkinson’s responded positively to fall 
reduction programmes but that effect had been counterbalanced 
with deterioration among those at the worse end of the spectrum 
producing a non-significant overall result. Although we have a 
number of subgroup analyses in PDSAFE, the results are consis-
tent with other published estimates reflecting a similar pattern: 
those in the moderate disease group, and in the middle group 
with respect to number of falls prior to the trial had a positive 
effect from PDSAFE with a 30% reduction in FRR (95% CI 50% 
to 5% reduction) in the first 6 months following randomisation. 
However, there was an increase in FRR of 43% (95% CI 4% to 
95%) helpful for the moderate disease group, more or different 
supervised therapy may have been required for those with 
freezing of gait and greater disease severity (more likely to have 
additional cognitive impairment) as they could have been more 
challenged by fall avoidance strategies and experienced greater 
difficulty with engaging in unsupervised sessions, thus limiting 
the intensity of practice and the effects.
A number of previous trials2 have shown the benefits of exer-
cise on risk factors for falling. In PDSAFE balance, functional 
strength and falls efficacy were targeted in the treatment and 
our analysis of secondary outcomes demonstrated a consistent 
improvement across the whole PDSAFE group, that is, those 
with mild, moderate and severe disease. These results support 
those of others2 highlighting the positive effects of exercise 
for balance and gait ability. Interventions in previous trials 
have largely been delivered outside the home setting but our 
current results demonstrate similar findings from interven-
tions within the home environment. A positive PDSAFE effect 
on near falls, an indicator of instability and reflective of the 
improvements in balance, was also reported. Near falls among 
PwP have been reported by Gazibara et al40 and Ashburn et 
al8 and are often related to stumbling or balance loss and 
have been observed to predispose falling in the general older 
population.41 As previously highlighted, all participants, even 
those with cognitive impairments, greater disease severity and 
freezing of gait, showed improvements in their balance scores 
and FES. We suggest this indicates these participants were able 
to comply with exercise but were not able to benefit from the 
more demanding fall prevention programme possibly because 
of the need to react and respond in a timely way at moments 
of instability.
A limitation of our research was the incomplete 12-month 
assessment on our sample, a consequence of restricted funding. 
All participants in our trial were followed to 6 months, the 
point of primary outcome, but the last 132 recruits could not 
be followed to 1 year after randomisation resulting in a smaller 
sample at 12 months impacting on the interpretation of long-
term follow-up, including the economic evaluation.
COnCluSIOn
PDSAFE did not reduce falls in the overall heterogeneous sample 
of PwP. The treatments were personalised to individual needs 
within the structure of the PDSAFE concept but the package 
may not have adequately addressed the range of profiles across 
the disease spectrum. Those with more severe disease may have 
found implementing the fall avoidance movement strategies too 
challenging or they needed more training time; secondary anal-
ysis showed diverse responses to the intervention. Secondary 
outcome measures demonstrated improvement in balance, 
functional strength and falls efficacy with a reduction in near 
falls across the whole sample. Further confirmatory trials of 
fall prevention on targeted groups of PwP are recommended.
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